The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient
- PMID: 10848940
- DOI: 10.1046/j.1524-4725.2000.00003.x
The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient
Abstract
Background: Imiquimod 5% cream has been used effectively to treat superficial basal cell carcinomas (BCCs).
Objective: The purpose of this study is to examine the effectiveness, tolerability, and desirability of imiquimod 5% cream in treating superficial non-facial basal cell carcinomas in a patient with basal cell nevus syndrome.
Methods: Three biopsy-proven nonfacial BCCs were treated for 18 weeks with once daily application of 5% imiquimod cream. The lesions were then removed to search histologically for residual tumor.
Results: The two adequately treated tumors revealed no residual BCC upon removal. Our patient reported that he tolerated the treatment but he would not desire this treatment again based on the length of treatment time and the degree of local inflammation at the treatment sites.
Conclusion: Imiquimod 5% cream appears to be effective in eradicating superficial nonfacial BCCs. The degree of local inflammatory response may affect the patients' tolerability of treatment and therefore patient compliance.
Similar articles
-
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.J Am Acad Dermatol. 2004 May;50(5):722-33. doi: 10.1016/j.jaad.2003.11.066. J Am Acad Dermatol. 2004. PMID: 15097956 Clinical Trial.
-
The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome.Clin Exp Dermatol. 2003 Nov;28 Suppl 1:19-23. doi: 10.1046/j.1365-2230.28.s1.7.x. Clin Exp Dermatol. 2003. PMID: 14616807
-
An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream.J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S240-8. doi: 10.1067/mjd.2002.126583. J Am Acad Dermatol. 2002. PMID: 12271286
-
Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.Dermatol Surg. 2002 May;28(5):427-9. doi: 10.1046/j.1524-4725.2002.01231.x. Dermatol Surg. 2002. PMID: 12030878 Review.
-
Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature.Dermatol Surg. 2002 Apr;28(4):344-6. doi: 10.1046/j.1524-4725.2002.01140.x. Dermatol Surg. 2002. PMID: 11966794 Review.
Cited by
-
Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management.Yale J Biol Med. 2015 Jun 1;88(2):167-79. eCollection 2015 Jun. Yale J Biol Med. 2015. PMID: 26029015 Free PMC article. Review.
-
[Hereditary tumor syndromes. Cutaneous manifestations and molecular pathogenesis of Gorlin and Cowden syndromes].Hautarzt. 2004 Oct;55(10):942-51. doi: 10.1007/s00105-004-0800-x. Hautarzt. 2004. PMID: 15349693 Review. German.
-
Management of superficial basal cell carcinoma: focus on imiquimod.Clin Cosmet Investig Dermatol. 2009 Jun 11;2:65-75. doi: 10.2147/ccid.s3507. Clin Cosmet Investig Dermatol. 2009. PMID: 21436969 Free PMC article.
-
Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).Antimicrob Agents Chemother. 2001 Nov;45(11):3059-64. doi: 10.1128/AAC.45.11.3059-3064.2001. Antimicrob Agents Chemother. 2001. PMID: 11600356 Free PMC article.
-
Advances in the use of topical imiquimod to treat dermatologic disorders.Ther Clin Risk Manag. 2008 Feb;4(1):87-97. doi: 10.2147/tcrm.s1109. Ther Clin Risk Manag. 2008. PMID: 18728724 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
